Law Offices of Howard G. Smith LLP Continues Investigation of Pharmaceutical Product Development, Inc.

Law Offices of Howard G. Smith is continuing its investigation of potential claims against the Board of Directors of Pharmaceutical Product Development, Inc. ("PPD" or the "Company") PPDI -0.43% related to the proposed acquisition of the Company to an affiliate of The Carlyle Group and Hellman & Friedman. The transaction is valued at approximately $3.9 billion or $33.25 per share and is expected to close by the end of fourth quarter 2011.The investigation concerns whether the Board of Directors of PPD breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price skyrocketed from $24.70 on August 8, 2011 to $32.28 on August 18, 2011. Further, at least one analyst has set a target price for the Company's stock at $38.00.